The positive predictivities (the ability of the test to correctly predict the presence of disease) for ovarian cancer were above 50 percent (59.57%, 58.24%, and 61.67% for microRNA-204, CA125, and CA19.9, respectively). This evidence concerns the gene MUC16 and ovarian carcinoma.